Modulation of human IGF binding protein-3 activity by structural modification

https://doi.org/10.1016/0955-2235(95)00004-6Get rights and content

Abstract

To delinate regions of IGFBP-3 involved in ligand and cell-surface binding, DNAs encoding human IGFBP-3[1–264] and several variants were transfected into CHO cells. Of three deletion (Δ) mutants, IGFBP-3[1–88], [1–184], and [Δ89–184], none bound IGF-I tracer by ligand blotting, although all were detectable by immunoblotting. No ALS binding was detectable, as predicted by the lack of IGF binding. Normal-sequence IGFBP-3 associated with the CHO cells and was partly displaceable by IGF-I. Whereas IGFBP-3[1–88] and [1–184] failed to cell-associate, the non-IGF-binding central deletion variant [Δ89–184] did associate with CHO cells but was not displaced by IGF-I. To further examine the role of the carboxy-terminal domain in cell-association, the basic sequence IGFBP-3[228–232] (KGRKR) was altered to the corresponding IGFBP-1 residues MDGEA, a major charge reversal. This variant showed reduced IGF-I binding, and bound ALS with decreased affinity as determined by Scatchard analysis. It showed no cell binding, implicating the basic domain in cell-association. We conclude that, whereas the central and carboxy-terminal domain deletions fail to bind IGF-I, the ability to cell associate requires the carboxy-terminal but not the central domain. Specifically, the basic region [228–232] is essential for cell binding, and also affects IGF-I binding, and independently, ALS affinity.

References (21)

  • R.C. Baxter et al.

    Structural determinants of binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3

    J Biol Chem

    (1992)
  • S.L.S. Drop et al.

    Structural aspects of the IGFBP family

    Growth Regul

    (1992)
  • J. Zapf

    Physiological role of the insulin-like growth factor binding proteins

    Eur J Endocrinol

    (1995)
  • C.A. Conover

    Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3

    Endocrinology

    (1991)
  • J.L. Martin et al.

    Insulin-like growth factor-I (IGF-I) and transforming growth factor-β1 release IGF-binding protein-3 from fibroblasts by different mechanisms

    Endocrinology

    (1992)
  • J.I. Jones et al.

    Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I

    J Cell Biol

    (1992)
  • G.L. Francis et al.

    Molecular interactions of IGF-I and IGF-II with their binding proteins and receptors

  • B.A. Booth et al.

    IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal binding domain

    Growth Regul

    (1995)
  • R.C. Baxter

    Glycosaminoglycans inhibit formation of the 140 kDa insulin-like growth factor-binding protein complex

    Biochem J

    (1990)
  • S.R. Leong et al.

    Structure and functional expression of the acid-labile subunit of the insulin-like growth factor-binding protein complex

    Mol Endocrinol

    (1992)
There are more references available in the full text version of this article.

Cited by (0)

View full text